Payment overview · 2025
General Payments
$55,905.04
100 reported records · 20 companies
Healthcare provider profile · identity verified
Mitchell Alin Jackson, MD
Allopathic & Osteopathic Physicians|Ophthalmology · LAKE VILLA, IL · NPI 1902958929
Verified facts
What the public records show
CMS Open Payments records show Mitchell Alin Jackson, MD received $55,905.04 in general payments during 2025 across 100 reported records.
Bausch & Lomb Americas Inc. accounted for 52.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Flarex, Miebo, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Simbrinza as an associated drug or biological on 1563 records involving 637 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Simbrinza by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Prolensa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xiidra by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FLAREX as an associated drug or biological on 39 records involving 37 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Flarex by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $29,598.43 | 52.9% | 42 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $13,816.44 | 24.7% | 19 | 2025 |
| LENSAR, Inc. | Unresolved — no canonical attribution shown | $4,208.22 | 7.5% | 4 | 2025 |
| Carl Zeiss Meditec, Inc. | Unresolved — no canonical attribution shown | $2,400.00 | 4.3% | 1 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $2,290.76 | 4.1% | 4 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $1,500.00 | 2.7% | 1 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $596.21 | 1.1% | 8 | 2025 |
| Microsurgical Technology, Inc. | Unresolved — no canonical attribution shown | $400.78 | 0.7% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $203.86 | 0.4% | 4 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $161.72 | 0.3% | 2 | 2025 |
| OCULUS, Inc. | Unresolved — no canonical attribution shown | $141.24 | 0.2% | 1 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $125.00 | 0.2% | 1 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $113.80 | 0.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $109.12 | 0.2% | 3 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $80.47 | 0.1% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.06 | 0.1% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $31.69 | 0.1% | 1 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $27.89 | 0.1% | 1 | 2025 |
| NEW WORLD MEDICAL,INC. | Unresolved — no canonical attribution shown | $26.10 | 0.1% | 2 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $20.25 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $25,562.50 | 13 |
| Honoraria | $11,600.00 | 2 |
| Compensation for serving as faculty or as a speaker for a medical education program | $10,275.00 | 4 |
| Food and Beverage | $5,536.62 | 69 |
| Travel and Lodging | $2,930.92 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $13,340.11 | 10 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $11,832.48 | 22 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $11,591.76 | 19 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $5,111.68 | 3 | 2025 |
Source payment records
|
|||||
| LENSAR LASER SYSTEM Normalized: lensar laser system |
Device | LENSAR, Inc. | $4,208.22 | 4 | 2025 |
Source payment records
|
|||||
| Crystalens Accommodating IOL (AT-52AO) Normalized: crystalens accommodating iol at 52ao |
Device | Bausch & Lomb Americas Inc. | $3,400.00 | 1 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $2,550.00 | 3 | 2025 |
Source payment records
|
|||||
| CALLISTO eye Normalized: callisto eye |
Device | Carl Zeiss Meditec, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| CIRRUS HD-OCT Normalized: cirrus hd oct |
Device | Carl Zeiss Meditec, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| IOLMaster 700 Normalized: iolmaster 700 |
Device | Carl Zeiss Meditec, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| MEL 90 Normalized: mel 90 |
Device | Carl Zeiss Meditec, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| VisuMax Normalized: visumax |
Device | Carl Zeiss Meditec, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $2,290.76 | 4 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $1,500.00 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $1,500.00 | 1 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $287.38 | 6 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $203.86 | 4 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $161.72 | 2 | 2025 |
Source payment records
|
|||||
| NA Normalized: na |
Device | OCULUS, Inc. | $141.24 | 1 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| KXL system (not refurbished) Normalized: kxl system not refurbished |
Device | Glaukos Corporation | $115.31 | 1 | 2025 |
Source payment records
|
|||||
| Xelpros Normalized: xelpros |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $114.82 | 1 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $113.80 | 1 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $80.47 | 2 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $61.57 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $53.06 | 1 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| FLAREX Normalized: flarex |
Drug | Harrow Eye, LLC | $41.50 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $39.59 | 2 | 2025 |
Source payment records
|
|||||
| IHEEZO Normalized: iheezo |
Drug | Harrow Eye, LLC | $38.23 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $31.69 | 1 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $27.89 | 1 | 2025 |
Source payment records
|
|||||
| Ahmed Glaucoma Valve Normalized: ahmed glaucoma valve |
Device | NEW WORLD MEDICAL,INC. | $26.10 | 2 | 2025 |
Source payment records
|
|||||
| Clearpath Normalized: clearpath |
Device | NEW WORLD MEDICAL,INC. | $26.10 | 2 | 2025 |
Source payment records
|
|||||
| Kahook Dual Blade Normalized: kahook dual blade |
Device | NEW WORLD MEDICAL,INC. | $26.10 | 2 | 2025 |
Source payment records
|
|||||
| Streamline Normalized: streamline |
Device | NEW WORLD MEDICAL,INC. | $26.10 | 2 | 2025 |
Source payment records
|
|||||
| Via360 Normalized: via360 |
Device | NEW WORLD MEDICAL,INC. | $26.10 | 2 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $20.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FLAREX flarex |
2025 | Flarex | 2024 | 59 | exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Simbrinza open payments reported associated product |
CMS Open Payments — General Payments 1563 supporting records · 637 recipient NPIs · example record 1207357100 |
Simbrinza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
67 | 55 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | FLAREX open payments reported associated product |
CMS Open Payments — General Payments 39 supporting records · 37 recipient NPIs · example record 1236210819 |
Flarex · 2024 Exact normalized brand match · 1 Part D row |
59 | 51 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Moxifloxacin | Moxifloxacin Hcl | 91 | 85 |
| Prolensa | Bromfenac Sodium | 67 | 55 |
| Besivance | Besifloxacin Hcl | 63 | 59 |
| Flarex | Fluorometholone Acetate | 59 | 51 |
| Latanoprost | Latanoprost | 41 | 15 |
| Loteprednol Etabonate | Loteprednol Etabonate | 30 | 30 |
| Miebo | Perfluorohexyloctane/Pf | 28 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 28 | 24 |
| Ilevro | Nepafenac | 18 | 15 |
| Xiidra | Lifitegrast | 16 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Lotemax Sm | Loteprednol Etabonate | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $55,905.04 · 100 records | Bausch & Lomb Americas Inc. | ACTHAR, Ahmed Glaucoma Valve, CALLISTO eye, CATALYS SYSTEM, CIRRUS HD-OCT, Cequa, Clareon PanOptix Pro, Clearpath, Crystalens Accommodating IOL (AT-52AO), DEXTENZA, DURYSTA, FLAREX, IHEEZO, IOLMaster 700, KXL system (not refurbished), Kahook Dual Blade, LENSAR LASER SYSTEM, LIGHT ADJUSTABLE LENS (LAL), MEL 90, MIEBO, NA, OCT OPHTHALMOSCOPE, OXERVATE, PANORAMIC OPHTHALMOSCOPE, PURIFIED CORTROPHIN GEL, Photrexa Viscous and Photrexa, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RYZUMVI, Streamline, TYRVAYA, VEVYE, VYZULTA, Via360, VisuMax, XDEMVY, XIIDRA, Xelpros, enVista Envy IOL, enVista MX60 IOL | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Flarex play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error